ALX Oncology Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
ALX Oncology is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing therapies that strengthen the immune system to treat cancer and extend patients’ lives. Its lead candidate, evorpacept, is being studied as a potential key component of immuno-oncology strategies, with multiple ongoing trials across a broad range of cancer indications. The company operates as a mid-sized biopharma firm, advancing a portfolio of cancer therapies through clinical development. In April 2026, ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer to lead development and operations.